Novartis | NOVN - Stock


Novartis reported $6.29B in Stock for its fiscal quarter ending in March of 2026.





Stock Change Date
AbbVie USD 5.05B 98M Mar/2026
Alcon AG USD 2.44B 47M Mar/2026
Almirall EUR 178.13M 1.54M Dec/2025
Amgen USD 6.19B 39M Mar/2026
AstraZeneca USD 6.57B 13M Mar/2026
Autolus Therapeutics Ltd USD 33.23M 24K Mar/2026
Bayer EUR 12.34B 3M Dec/2025
Biogen USD 1.95B 219.1M Mar/2026
Bristol-Myers Squibb USD 2.76B 66M Mar/2026
Eli Lilly USD 14.53B 785M Mar/2026
Fresenius EUR 2.61B 19M Dec/2025
Fresenius Medical Care EUR 2.3B 162.24M Mar/2026
Genmab DKK 13M 1000K Jun/2025
Gilead Sciences USD 1.91B 140M Mar/2026
GlaxoSmithKline GBP 6.16B 233M Mar/2026
GRIFOLS EUR 3.35B 213.23M Jun/2025
Hikma Pharmaceutical USD 1.08B 96M Jun/2025
J&J USD 14.58B 392M Mar/2026
Lakefront Biotherapeutics EUR 17.69M 4.8M Mar/2026
Lonza CHF 1.68B 163M Dec/2025
Merck EUR 4.56B 52M Dec/2025
Merck USD 6.48B 179M Mar/2026
Novartis USD 6.29B 17M Mar/2026
Novartis USD 6.42B 114M Sep/2025
Novo Nordisk DKK 45.65B 21.26B Jun/2025
Orion EUR 456.3M 12.6M Dec/2025
Pfizer USD 10.67B 13M Mar/2026
Philips EUR 2.87B 390M Dec/2025
Recordati EUR 539.8M 34.61M Dec/2025
Regeneron Pharmaceuticals USD 3.1B 97.2M Mar/2026
Roche Holding CHF 7.6B 9M Jun/2025
Sanofi EUR 22.69B 1.81B Dec/2025
UCB EUR 1.31B 173M Dec/2024